Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
生物类似药地诺单抗候选药物(Arylia)与参考产品(Prolia®)在绝经后骨质疏松症中的疗效和安全性比较:一项III期、随机、双臂、双盲、平行、阳性对照、非劣效性临床试验
期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-022-02840-8
Jamshidi, Ahmadreza; Vojdanian, Mahdi; Soroush, Mohsen; Akbarian, Mahmoud; Aghaei, Mehrdad; Hajiabbasi, Asghar; Mirfeizi, Zahra; Khabbazi, Alireza; Alishiri, Gholamhosein; Haghighi, Anousheh; Salimzadeh, Ahmad; Karimzadeh, Hadi; Shirani, Fatemeh; Fard, Mohammad Reza Hatef; Nazarinia, MohammadAli; Soroosh, Soosan; Anjidani, Nassim; Gharibdoost, Farhad